PMID- 19689039
OWN - NLM
STAT- MEDLINE
DCOM- 20090915
LR  - 20151119
IS  - 0033-2240 (Print)
IS  - 0033-2240 (Linking)
VI  - 66
IP  - 3
DP  - 2009
TI  - [Anti-IgE therapy in persistent allergic asthma].
PG  - 141-4
AB  - Asthma is a chronic inflammatory disease of airways. Approximately 40% of asthma 
      cases can be attributed to atopy. An increased immunoglobulin E (IgE) production 
      is the strongest predisposing factor for the development of asthma. IgE is a key 
      component of asthma pathophysiology and contributes to both the early- and 
      late-phase inflammatory cascade in the airways. Omalizumab is a recombinant 
      anti-IgE monoclonal antibody developed for the treatment of allergic diseases 
      associated with high circulating IgE levels. By reducing serum IgE levels, as 
      well as FceRI and FceRII receptor expression on inflammatory cells, omalizumab 
      inhibits development of inflammatory cascade. Omalizumab is currently the only 
      IgE-targeted therapy approved by EMEA (European Agency for the Evaluation of 
      Medicinal Products) and FDA (Food and Drug Administration) for asthma treatment. 
      It is efficacious in the treatment of moderate-to-severe and severe persistent 
      allergic asthma poorly controlled with regular treatment. The drug reduces 
      symptoms, exacerbations, emergency visits, hospitalizations, inhaled and systemic 
      corticosteroid and rescue medication requirements and improves quality of life.
FAU - Skiepko, Roman
AU  - Skiepko R
AD  - Klinika Alergologii i Chorob Wewnetrznych, Uniwersytetu Medycznego w Bialymstoku. 
      alergol@amwb.edu.pl
FAU - Zietkowski, Ziemowit
AU  - Zietkowski Z
FAU - Tomasiak-Lozowska, Maria Magdalena
AU  - Tomasiak-Lozowska MM
FAU - Bodzenta-Lukaszyk, Anna
AU  - Bodzenta-Lukaszyk A
LA  - pol
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Przeciwcialo monoklonalne anty-IgE w leczeniu przewleklej ciezkiej astmy.
PL  - Poland
TA  - Przegl Lek
JT  - Przeglad lekarski
JID - 19840720R
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Recombinant Proteins)
RN  - 0 (anti-IgE antibodies)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Anti-Asthmatic Agents/*therapeutic use
MH  - Antibodies, Anti-Idiotypic/*therapeutic use
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Asthma/*drug therapy/immunology
MH  - Humans
MH  - Immunoglobulin E/biosynthesis
MH  - Omalizumab
MH  - Quality of Life
MH  - Recombinant Proteins/therapeutic use
MH  - Respiratory Hypersensitivity/complications
RF  - 50
EDAT- 2009/08/20 09:00
MHDA- 2009/09/16 06:00
CRDT- 2009/08/20 09:00
PHST- 2009/08/20 09:00 [entrez]
PHST- 2009/08/20 09:00 [pubmed]
PHST- 2009/09/16 06:00 [medline]
PST - ppublish
SO  - Przegl Lek. 2009;66(3):141-4.